Saturday, January 29, 2022


US to distribute 6.4 million Covid vaccine doses in first tranche

Latest figures on Tuesday showed that the country had recorded a total of 259,600 Covid deaths and 12.5 million cases -- with over 2,000 deaths and 167,000 new cases in just the last 24 hours.

Serum Institute of India CEO expresses delight at Covishield vaccine efficacy

The Oxford-AstraZeneca vaccine is being made in partnership with Serum Institute.

AstraZeneca: COVID-19 vaccine ‘highly effective’ prevention

A vaccine developed by AstraZeneca and the University of Oxford prevented 70% of people from developing the coronavirus in late-stage trials, the team reported Monday.

Tuberculosis vaccine linked to lower risk of contracting Covid-19

In the new study, published in The Journal of Clinical Investigation, the research team tested the blood of more than 6,000 healthcare workers for evidence of antibodies to SARS-CoV-2.

G20 urged to fill $4.5 bn gap in global Covid-19 vaccine fund

The Covid-19 pandemic has infected more than 55 million people and caused more than 1.3 million deaths worldwide.

Haryana Health Minister Anil Vij administered trial dose of Covaxin

He had offered to be the first volunteer for the third phase trial of Covaxin, which started in the state today.

Pfizer/BioNTech to seek emergency vaccine approval in US on Friday

The scientific head of the US operation to develop a vaccine, Moncef Slaoui said Monday that the green light would probably come in December.

Summer of 2021 will be almost normal: Microsoft co-founder Bill Gates

"Very likely by the summer, a lot of things will be back to normal... If vaccine approvals come along quickly," Gates said in a television interview on Thursday night.

Oxford Covid vax shows strong immune response in older adults

The study, published in The Lancet medical journal, suggest that those aged over 70 -- who are at higher risk of serious illness and death from Covid-19 -- could build robust immunity to the novel Coronavirus.

Oxford University COVID-19 vaccine ‘encouraging’ for older age groups

The team is also testing whether the vaccine stops people developing COVID-19 in larger Phase 3 trials and early results from this crucial stage are expected in the coming weeks.

Pfizer shares surge nearly 4 per cent on vaccine report

Global drugmakers Pfizer and BioNTech said on Wednesday that their COVID-19 vaccine was found 95 per cent effective in the final analysis of the Phase 3 trial.

Phase 3 trial of Covaxin to begin in Haryana on Nov 20

Bharat Biotech had on Monday said the Phase 3 trial of Covaxin will involve 26,000 volunteers across 25 centres in India and is being conducted in partnership with the ICMR.

Tipping point

Developments on vaccine front offer a tentative timeline on when it could be available on a mass scale

Sensex, Nifty scale record high levels supported by positive vaccine news

Tata Steel was the top gainer in the Sensex pack, rising over 4 per cent, followed by Bharti Airtel, SBI, HDFC Bank, M&M, Asian Paints and Reliance Industries.

New vaccine breakthrough lifts global hope against pandemic

Moderna, whose results stem from a clinical trial of more than 30,000 participants, expects to have approximately 20 million doses ready to ship in the United States by year-end.

Latest News

- Advertisement -